Is Obesity Associated With Increased Risk of Deep Vein Thrombosis or Pulmonary Embolism After Hip and Knee Arthroplasty? A Large Database Study.
Aged
Aged, 80 and over
Anticoagulants
/ therapeutic use
Arthroplasty, Replacement, Hip
/ adverse effects
Arthroplasty, Replacement, Knee
/ adverse effects
Body Mass Index
Databases, Factual
Female
Fibrinolytic Agents
/ therapeutic use
Humans
Male
Middle Aged
Obesity
/ diagnosis
Pulmonary Embolism
/ diagnosis
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
United States
/ epidemiology
Venous Thrombosis
/ diagnosis
Journal
Clinical orthopaedics and related research
ISSN: 1528-1132
Titre abrégé: Clin Orthop Relat Res
Pays: United States
ID NLM: 0075674
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
10
1
2019
medline:
24
12
2019
entrez:
10
1
2019
Statut:
ppublish
Résumé
Deep venous thrombosis (DVT) and pulmonary embolus (PE) remain an important cause of morbidity and mortality after THA and TKA. Prior recommendations have advocated for more aggressive prophylaxis for patients with obesity, whereas the evidence supporting these recommendations is conflicting and often based on underpowered studies. (1) What is the association between obesity and DVT and PE after primary and revision THA and TKA? (2) Is there a body mass index (BMI) threshold beyond which DVT and PE risk is elevated? We reviewed the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from 2008 to 2016 to evaluate the reported 30-day rates of DVT, PE, and combined venous thromboembolism (VTE) after primary THA, primary TKA, revision THA, and revision TKA according to BMI as a continuous variable and a categorical variable as defined by the World Health Organization cutoffs for underweight, normal weight, overweight, and obesity. This database is risk-adjusted and designed to capture complications after surgery, thus making it ideal for this study. The diagnosis of DVT and PE is included in the ACS-NSQIP database for any DVT or PE requiring treatment. Proximal versus distal DVT is not specified within the database. Multivariate logistic regression was performed to determine if obesity was independently associated with DVT and PE risk by controlling for age, sex, race, American Society of Anesthesiologists score, diabetes, hypertension, smoking status, general anesthesia, and hypoalbuminemia. After controlling for potential confounding variables such as medical comorbidities and procedure type, patients undergoing primary and revision THA and TKA with World Health Organization classification as underweight (BMI < 18.5 kg/m), overweight (BMI 25-29.9 kg/m), Class I obese (BMI 30-34.9 kg/m), Class II obese (BMI 35-39.9 kg/m), or Class III obese (BMI ≥ 40 kg/m) did not demonstrate an association with increased risk of DVT compared with patients classified as normal weight (BMI 18.5-25 kg/m). Compared with patients undergoing primary THA classified as normal weight, the risk of PE was elevated in patients with Class II obesity (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.23-4.50; p = 0.009) and all heavier categories. Compared with patients undergoing TKA classified as normal weight, the risk of PE was elevated in patients classified as overweight (OR, 1.56; 95% CI, 1.03-2.36; p = 0.035) and all heavier categories. This large administrative database study suggests that patient classification as overweight or obese is associated with increased risk of development of PE but not DVT after primary THA or TKA. Because aggressive pharmacologic anticoagulation regimens can decrease the DVT rate but have not been shown to affect the rate of PE or death, the data do not currently support increased anticoagulation in patients with obesity without other risk factors for VTE undergoing THA or TKA. Additional studies are required to refine VTE prophylaxis protocols to reduce PE risk while maintaining acceptable postoperative bleeding risk. Level III, therapeutic study.
Sections du résumé
BACKGROUND
Deep venous thrombosis (DVT) and pulmonary embolus (PE) remain an important cause of morbidity and mortality after THA and TKA. Prior recommendations have advocated for more aggressive prophylaxis for patients with obesity, whereas the evidence supporting these recommendations is conflicting and often based on underpowered studies.
QUESTIONS/PURPOSES
(1) What is the association between obesity and DVT and PE after primary and revision THA and TKA? (2) Is there a body mass index (BMI) threshold beyond which DVT and PE risk is elevated?
METHODS
We reviewed the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from 2008 to 2016 to evaluate the reported 30-day rates of DVT, PE, and combined venous thromboembolism (VTE) after primary THA, primary TKA, revision THA, and revision TKA according to BMI as a continuous variable and a categorical variable as defined by the World Health Organization cutoffs for underweight, normal weight, overweight, and obesity. This database is risk-adjusted and designed to capture complications after surgery, thus making it ideal for this study. The diagnosis of DVT and PE is included in the ACS-NSQIP database for any DVT or PE requiring treatment. Proximal versus distal DVT is not specified within the database. Multivariate logistic regression was performed to determine if obesity was independently associated with DVT and PE risk by controlling for age, sex, race, American Society of Anesthesiologists score, diabetes, hypertension, smoking status, general anesthesia, and hypoalbuminemia.
RESULTS
After controlling for potential confounding variables such as medical comorbidities and procedure type, patients undergoing primary and revision THA and TKA with World Health Organization classification as underweight (BMI < 18.5 kg/m), overweight (BMI 25-29.9 kg/m), Class I obese (BMI 30-34.9 kg/m), Class II obese (BMI 35-39.9 kg/m), or Class III obese (BMI ≥ 40 kg/m) did not demonstrate an association with increased risk of DVT compared with patients classified as normal weight (BMI 18.5-25 kg/m). Compared with patients undergoing primary THA classified as normal weight, the risk of PE was elevated in patients with Class II obesity (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.23-4.50; p = 0.009) and all heavier categories. Compared with patients undergoing TKA classified as normal weight, the risk of PE was elevated in patients classified as overweight (OR, 1.56; 95% CI, 1.03-2.36; p = 0.035) and all heavier categories.
CONCLUSIONS
This large administrative database study suggests that patient classification as overweight or obese is associated with increased risk of development of PE but not DVT after primary THA or TKA. Because aggressive pharmacologic anticoagulation regimens can decrease the DVT rate but have not been shown to affect the rate of PE or death, the data do not currently support increased anticoagulation in patients with obesity without other risk factors for VTE undergoing THA or TKA. Additional studies are required to refine VTE prophylaxis protocols to reduce PE risk while maintaining acceptable postoperative bleeding risk.
LEVEL OF EVIDENCE
Level III, therapeutic study.
Identifiants
pubmed: 30624321
doi: 10.1097/CORR.0000000000000615
pmc: PMC6382191
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
523-532Commentaires et corrections
Type : CommentIn
Références
JAMA Surg. 2019 Jan 1;154(1):65-72
pubmed: 30347089
J Arthroplasty. 2008 Oct;23(7 Suppl):2-5
pubmed: 18922368
J Bone Joint Surg Br. 2008 Feb;90(2):127-32
pubmed: 18256075
J Bone Joint Surg Br. 2006 Oct;88(10):1286-92
pubmed: 17012415
Ann Pharmacother. 2013 Jan;47(1):63-74
pubmed: 23324504
Acta Orthop. 2011 Aug;82(4):417-22
pubmed: 21657972
J Arthroplasty. 2017 Nov;32(11):3524-3528.e1
pubmed: 28634095
J Bone Joint Surg Am. 2017 Jan 18;99(2):91-98
pubmed: 28099298
Ann Pharmacother. 2012 Jan;46(1):79-88
pubmed: 22202495
J Arthroplasty. 2016 Oct;31(10):2237-40
pubmed: 27118182
J Arthroplasty. 2016 Dec;31(12):2880-2883
pubmed: 27369301
J Arthroplasty. 2015 May;30(5):849-53
pubmed: 25577726
Chest. 2012 Feb;141(2 Suppl):7S-47S
pubmed: 22315257
Surg Technol Int. 2012 Dec;22:251-9
pubmed: 23292672
N Engl J Med. 2000 Dec 14;343(24):1758-64
pubmed: 11114314
J Bone Joint Surg Br. 2008 Apr;90(4):424-9
pubmed: 18378913
Anesthesiology. 2003 Sep;99(3):552-60; discussion 5A
pubmed: 12960538
Clin Orthop Relat Res. 2017 Sep;475(9):2205-2213
pubmed: 28569372
Clin Orthop Relat Res. 2014 Feb;472(2):482-8
pubmed: 23817755
J Bone Joint Surg Am. 2013 Jul 17;95(14):1256-64
pubmed: 23864173
J Arthroplasty. 2017 Sep;32(9S):S157-S161
pubmed: 28214257
Arch Intern Med. 2000 Mar 13;160(5):669-72
pubmed: 10724052
J Bone Joint Surg Br. 2007 Jun;89(6):799-807
pubmed: 17613508
Orthopedics. 2009 Dec;32(12 Suppl):74-8
pubmed: 20201480
J Arthroplasty. 2016 Sep;31(9 Suppl):83-6
pubmed: 27094242
Thrombosis. 2012;2012:837896
pubmed: 23029611
Thromb J. 2015 Feb 14;13:10
pubmed: 25713501
Clin Orthop Relat Res. 2013 Oct;471(10):3358-66
pubmed: 23670675
J Bone Joint Surg Am. 2009 Jul;91(7):1756-7
pubmed: 19571100
Chest. 2008 Jun;133(6 Suppl):381S-453S
pubmed: 18574271
Curr Vasc Pharmacol. 2011 Jan;9(1):33-41
pubmed: 21044024
Chest. 2009 Feb;135(2):513-520
pubmed: 19201714
J Arthroplasty. 2009 Sep;24(6 Suppl):77-83
pubmed: 19628366